258 related articles for article (PubMed ID: 23907723)
1. Teriparatide treatment in adult patients with osteogenesis imperfecta type I.
Gatti D; Rossini M; Viapiana O; Povino MR; Liuzza S; Fracassi E; Idolazzi L; Adami S
Calcif Tissue Int; 2013 Nov; 93(5):448-52. PubMed ID: 23907723
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.
Orwoll ES; Shapiro J; Veith S; Wang Y; Lapidus J; Vanek C; Reeder JL; Keaveny TM; Lee DC; Mullins MA; Nagamani SC; Lee B
J Clin Invest; 2014 Feb; 124(2):491-8. PubMed ID: 24463451
[TBL] [Abstract][Full Text] [Related]
3. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
4. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
Boonen S; Marin F; Obermayer-Pietsch B; Simões ME; Barker C; Glass EV; Hadji P; Lyritis G; Oertel H; Nickelsen T; McCloskey EV;
J Clin Endocrinol Metab; 2008 Mar; 93(3):852-60. PubMed ID: 18160462
[TBL] [Abstract][Full Text] [Related]
5. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
Rauch F; Munns CF; Land C; Cheung M; Glorieux FH
J Bone Miner Res; 2009 Jul; 24(7):1282-9. PubMed ID: 19257821
[TBL] [Abstract][Full Text] [Related]
6. Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy.
Nicol L; Wang Y; Smith R; Sloan J; Nagamani SC; Shapiro J; Lee B; Orwoll E
J Bone Miner Res; 2018 Feb; 33(2):307-315. PubMed ID: 29044725
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
8. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
[TBL] [Abstract][Full Text] [Related]
10. Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma.
Arantes HP; Barros ER; Kunii I; Bilezikian JP; Lazaretti-Castro M
J Bone Miner Res; 2011 Dec; 26(12):2823-6. PubMed ID: 21997141
[TBL] [Abstract][Full Text] [Related]
11. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study.
Minne H; Audran M; Simões ME; Obermayer-Pietsch B; Sigurðsson G; Marín F; Dalsky GP; Nickelsen T;
Curr Med Res Opin; 2008 Nov; 24(11):3117-28. PubMed ID: 18838053
[TBL] [Abstract][Full Text] [Related]
12. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
14. Intravenous neridronate in adults with osteogenesis imperfecta.
Adami S; Gatti D; Colapietro F; Fracassi E; Braga V; Rossini M; Tatò L
J Bone Miner Res; 2003 Jan; 18(1):126-30. PubMed ID: 12510813
[TBL] [Abstract][Full Text] [Related]
15. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
16. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
Mok J; Brown C; Moore AEB; Min SS; Hampson G
Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
[TBL] [Abstract][Full Text] [Related]
17. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
Bradbury LA; Barlow S; Geoghegan F; Hannon RA; Stuckey SL; Wass JA; Russell RG; Brown MA; Duncan EL
Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105
[TBL] [Abstract][Full Text] [Related]
18. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.
Liu W; Lee B; Nagamani SCS; Nicol L; Rauch F; Rush ET; Sutton VR; Orwoll E
J Clin Endocrinol Metab; 2023 Jun; 108(7):1787-1796. PubMed ID: 36658750
[TBL] [Abstract][Full Text] [Related]
19. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
20. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
